Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.

about

Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.

Item

http://www.wikidata.org/entity/Q45742313

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy and safety of lixisen ...... diabetes and renal impairment.

@en

Efficacy and safety of lixisen ...... diabetes and renal impairment.

@nl

type

Item

label

Efficacy and safety of lixisen ...... diabetes and renal impairment.

@en

Efficacy and safety of lixisen ...... diabetes and renal impairment.

@nl

prefLabel

Efficacy and safety of lixisen ...... diabetes and renal impairment.

@en

Efficacy and safety of lixisen ...... diabetes and renal impairment.

@nl

P1476

Efficacy and safety of lixisen ...... diabetes and renal impairment.

@en

P2093

Elena Nikonova

http://www.w3.org/2001/XMLSchema#string

Juan M Arteaga

http://www.w3.org/2001/XMLSchema#string

Marina Shestakova

http://www.w3.org/2001/XMLSchema#string

Ricardo Gómez-Huelgas

http://www.w3.org/2001/XMLSchema#string

William Stager

http://www.w3.org/2001/XMLSchema#string

P2860

Pancreatic regulation of glucose homeostasis

Hypoglycemia in Patients with Diabetes and Renal Disease

Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications

Prediction of creatinine clearance from serum creatinine

Standards of medical care in diabetes--2013

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study.

Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

P304

1594-1601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1111/DOM.12986

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giulio Marchesini

Lawrence A Leiter

Markolf Hanefeld

P577

2017-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28449324

http://www.w3.org/2001/XMLSchema#string

P932

5655920

http://www.w3.org/2001/XMLSchema#string